这一技术或使肾病患者彻底摆脱透析 dnf清理废旧钢筋

Biochip or human end dialysis stocks on air sina finance Level2:A shares of sina finance: App speed Kanpan live on-line blogger to tutor (02) securities times net month 21 days according to the latest news of the Vanderbilt University, the School researchers are using microchip membrane and living cells to create a kidney implantable artificial kidney, the waste can be filtered out by the body. This technology or to completely get rid of dialysis patients with nephropathy. The University Medical Center nephrologists, associate professor of medicine at William · Faisal said, they are creating a biological mixing device, can simulate the renal clearance of waste, salt and water, let the patient no longer need dialysis. It is reported that this is the key equipment of micro chip silicon nanotechnology, the computer technology and microelectronics industry in chips. This chip is not expensive, but very precise, the membrane can be used as an ideal. The key to use microchip is not filtered, they still support live kidney cell life. This equipment organization will not cause immune reactions, so it won’t be rejected by the body. Faisal said, but it is different and organ transplantation, it is not adapt to the immune, but naturally rely on blood operation patients. And it required energy can be completely from the patient’s own heart supply. Many patients who needed dialysis are eager to join the human experiment in the future, currently has a long list of human trials are expected to begin by the end of 2017. Some analysts believe that the bio chip technology is a high-tech research and development and production at the end of twentieth Century with the "human genome project", are being used by more and more areas, its business has very broad application prospects. The global bio chip market in the rapid diagnosis demand and other factors, at a CAGR of 19.1%. In fact, the biochip is widely used, has been widely used in various research and practice, life science and clinical medical research, drug design, environmental protection, agriculture, military and other fields. These will undoubtedly bring great social and economic benefits. With the economic and social research and broad prospects. Therefore, some famous international investors and scientists are optimistic about the prospects of this technology, biochip and related products that are likely to exceed the value of microelectronic chips, become the biggest first Century high-tech industry, has enormous commercial potential. Analysis pointed out that with the rapid development of biotechnology, bio chip will bring a profound revolution to our life. The revolution for the sustainable development of the whole world will play an inestimable contribution. A shares of listed companies, with bio chip core technology stocks worth focusing on. Qianshan medicine machine (300216) held in Hunan Wang Hao gene Biotechnology Co., Ltd. 79.73% stake. Wang Hao gene with the development of gene chip technology, pharmacogenomics application technology and other core technologies in the development of individualized drug therapy genetic testing products, Wang Hao gene is in the field of China leader and leading the world in most developed countries. At present the macro Hao gene has been successfully developed for hypertension, malignant tumor, diabetes, nerve system theory

生物芯片或助人类终结透析 概念股站上风口 新浪财经Level2:A股极速看盘 新浪财经App:直播上线 博主一对一指导   证券时报网()02月21日讯   据美国范德堡大学最新消息,该校研究人员正在用微芯片滤膜和活的肾脏细胞创造一种可植入的人工肾脏,能将身体产生的废物过滤出去。这一技术或使肾病患者彻底摆脱透析。该校医学中心肾病学家、医学副教授威廉姆·费塞尔说,他们正在创造一种生物混合设备,能模拟肾脏清除废物、盐和水,让病人不再需要透析。   据悉,这一设备的关键是硅纳米技术微芯片,其工艺与计算机微电子行业中的芯片一样。这种芯片并不昂贵,却很精密,可作为理想的滤膜。微芯片的关键用途还不止过滤,它们还是活肾脏细胞安身的支架。这种设备的组织不会引起免疫反应,所以不会被身体排斥。费塞尔说,但它和器官移植不同,它不是适应免疫的匹配,而是天然地依靠病人血液运作。且它所需能量可完全由病人自己的心脏供给。很多需要透析的病人都渴望能加入将来的人体实验,目前已有一串长长的名单,人体实验有望2017年底开始。   有分析认为,生物芯片是20世纪末随“人类基因组计划”的研究和发展而产生的一项高新技术,正在被越来越多的领域所应用,其商业应用前景十分广阔。全球生物芯片市场在快速诊断的需求高涨等要素影响下,正在以19.1%的年复合成长率扩大。   实际上,生物芯片用途广泛,在生命科学研究及实践、医学科研及临床、药物设计、环境保护、农业、军事等各个领域有着广泛的用武之地。这些无疑将会产生巨大的社会和经济效益。有着广泛的经济、社会及科研前景。因此,国际上一些著名投资者和科学家均看好这一技术前景,认为生物芯片以及相关产品产值有可能超过微电子芯片,成为下一世纪最大的高技术产业,具有巨大的商业潜力。分析指出,随着生物技术的迅速发展,生物芯片将给我们的生活带来一场深刻的革命。这场革命对于全世界的可持续发展都会起到不可估量的贡献。A股上市公司中,拥有生物芯片核心技术的个股值得重点关注。   千山药机(300216)持有湖南宏灏基因生物科技有限公司79.73%股权。宏灏基因拥有“基因芯片研制技术”、“药物基因组学应用技术”等核心技术,在个体化药物治疗基因检测产品的研制方面,宏灏基因是中国在该领域的领导者,并领先于世界多数发达国家。目前宏灏基因已经成功研发了针对高血压、恶性肿瘤、糖尿病、神经系统疾病、器官移殖差异性检测等个体化药物治疗基因检测芯片。   山东海化(000822)控股子公司深圳欣康基因数码科技有限公司,主要从事生物芯片的研制、销售。欣康基因网站显示,欣康基因是由山东海化和西安华洲生物技术有限公司投资兴建,第四军医大学全军基因芯片重点实验室提供技术支持的生物高新技术企业。公司主要致力于临床基因诊断、治疗等新技术的研发和推广,是国内首批具有国家批准资质文号的临床生物芯片的生产经营厂家。   东富龙(300171)2015年9月与上海伯豪生物技术有限公司及其股东方共同签署增资协议。增资完成后,东富龙医疗占伯豪生物的股权比例为34.0206%,成为伯豪生物第一大股东。伯豪生物主营业务为从事基因芯片及测序服务等,具体可以细分为微阵列芯片技术服务(又称生物芯片技术服务)、二代测序技术服务和生物标志物技术服务三类业务,目前已经构建了微阵列芯片平台、新一代测序平台等五大技术平台。   (证券时报网快讯中心) 新浪声明:此消息系转载自新浪合作媒体,新浪网登载此文出于传递更多信息之目的,并不意味着赞同其观点或证实其描述。文章内容仅供参考,不构成投资建议。投资者据此操作,风险自担。 进入【新浪财经股吧】讨论相关的主题文章: